ArticleAmerican journal of translational research2025
Kuanxiong aerosol attenuates post-myocardial infarction heart failure by immune modulation via the NOTCH1 pathway.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Kuanxiong aerosol for preventing acute mountain sickness: an exploratory small-sample randomized, placebo-controlled trial.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the mechanisms underlying the therapeutic effects of Kuanxiong aerosol (KXA) in heart failure after myocardial infarction (HFAMI).
methodsA HFAMI rat model was established. Echocardiography, H&E and TUNEL staining of heart tissue, and ELISA for HFAMI-related biomarkers were performed after KXA treatment. qPCR, Western blot, and flow cytometry were used to identify potential KXA targets in vivo and in vitro. Cell viability and apoptosis were evaluated using the Cell Counting Kit-8.
resultsKXA significantly decreased left ventricular end diastolic diameter (LVIDD, 6.49±0.40 mm, P<0.001) and left ventricular end-systolic dimension (LVISD, 3.72±0.27 mm, P<0.001), while increasing left ventricular ejection fraction (LVEF, 64.66±2.69%, P<0.001) and left ventricular fraction shortening (LVFS, 43.20±5.93%, P<0.001). KXA also suppressed cardiomyocyte apoptosis and reduced levels of NT-proBNP, ST2, IL-6, TNF-α, MMP2, and MMP9 (all P<0.05). Additionally, KXA reduced immune cell infiltration (Neutrophils, Macrophages, Th1, NK cells) and upregulated DLL4, NOTCH1, NICD, and Hes1 expression in the infarction zone. In doxorubicin-treated cells, KXA enhanced cell viability and upregulated Bcl-2, Bcl-xL, and NOTCH pathway proteins, while reducing cleaved caspase-3 (all P<0.05).
conclusionKXA improves HFAMI by modulating immune responses and activating the NOTCH1 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.